

MARKET RELEASE
Cryosite Limited (ASX: CTE)
13 July 2026

Trading Update – Full Year Results – 30 June 2026

Dear Shareholders,

Cryosite Limited (ASX: CTE) is pleased to provide the following update on its unaudited financial results for the twelve months to 30 June 2026.

Cryosite closes out FY2026 with revenue up 18% to \$16.7m and EBITDA up 27% to \$4.3m.

Financial Highlights

	FY2026	% Change	FY2025
Revenue	16.7	18%	14.1
EBITDA	4.3	27%	3.4
<i>EBITDA Margin</i>	<i>25.7%</i>	<i>+1.8pp</i>	<i>23.9%</i>
EBIT	3.4	35%	2.5
NPAT	2.3	20%	1.9
<i>NPAT Margin</i>	<i>13.5%</i>	<i>+0.2pp</i>	<i>13.3%</i>

Table 1. All figures unaudited.

Earnings again grew faster than revenue, as capacity utilisation of our Ferndell Street headquarters accelerated and margins continued to expand. The fourth quarter carried the momentum through to year-end, with June revenue of \$1.5m and EBITDA of \$0.4m.


Outlook

With the Ferndell Street cool room (2°C to 8°C) expansion completed and our Adderley Street facility build out progressing well, Cryosite's focus for FY2027 is converting this additional capacity into client activity. Our client pipeline is strong, and we look forward to updating shareholders as the year progresses.

These results are unaudited and remain subject to completion of the FY2026 audit process.

On behalf of the Board, thank you to the Cryosite team for another strong year of delivery, and to our shareholders and clients for their continued backing as we build into FY2027.

Kind regards,



Andrew Kerr
 Executive Director



MOBILE +61 483 840 860
EMAIL andrew.kerr@cryosite.com

Authorised for lodgement by the Board of the Company.

—END—

About Cryosite

Cryosite is a unique Australian company and a world-class specialist in providing outsourced clinical trial and biological depot services.

Established in 2000, Cryosite is highly experienced in clinical trial logistics. Our team is comprised of highly qualified scientists and clinical trials experts who ensure complex clinical trials are conducted with seamless efficiency and safety.

We manage the importation, receipt, storage, distribution and reverse logistics of specialized ambient, cold, frozen, ultra-frozen, liquid nitrogen clinical trial, pharmaceutical and biological products. Cryosite's third party depot services are professional, reliable and compliant; our people are experts in their respective fields and are approachable, ethical and responsive to clients' needs.

To learn more, please visit our [website](#) or [Cryosite's Investor Hub](#).

Ferndell Street Facility (Headquarters)

- 13a Ferndell Street, South Granville, NSW, 2142
- Building Area: ~1,800sqm
- GMP, GWP licenced
- Services include Clinical Trial and Biological:
 - Storage
 - Importation
 - Receipt
 - Labelling
 - Distribution
 - Secondary packaging
 - Reverse logistics
 - Expiry extension

Adderley Street Facility

- 100-104 Adderley Street West, Auburn, NSW, 2144
- ~15 minutes' drive from Ferndell Street
- Building Area: ~2,100sqm (clearance 9.1m)
- Services include:
 - Clinical Trial and Biological service expansion
 - Medical devices
 - Reverse logistics
 - Pallet storage
 - Talk to us about your requirements - contact@cryosite.com

